Clinical trials: Carcinomatosis
Peritoneal Carcinomatosis
Study in Patients With Peritoneal Carcinomatosis From CEA Overexpressing Digestive Cancer
The digestive cancer is the second cause of death worldwide. The presence of peritoneal carcinomatosis is common in the evolution of this type of cancer, as well as increased levels of ACE.
- Trial name
- FLUOCAR-1 (NCT02784028)
- Testing
- SGM-101
- Where
- France
- Volunteers
- 18 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
NSCLC, Brain Metastases
A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY)
Almonertinib is a three-generation epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI), which has shown competitive potential in the second-line treatment against first-generation TKIs.
- Conditions
- NSCLC, Brain Metastases, Leptomeningeal Metastasis
- Trial name
- NCT04778800
- Testing
- almonertinib, LM-first line treatment, LM-second line treatment
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Henan Cancer Hospital
Leptomeningeal Metastases
Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Cancer
Leptomeningeal metastases (LM) is a lethal complication of malignant tumors, characterized by tumor cell invasion and proliferation within the subarachnoid space.
- Trial name
- NCT06462092
- Testing
- Sacituzumab Govitecan, Pemetrexed
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Guangzhou Medical University
Breast Cancer, Leptomeningeal Metastasis
Microfluidic Device to Diagnose Leptomeningeal Metastasis in Breast Cancer
This study will prospectively enroll 36 evaluable subjects with breast cancer who are undergoing workup for clinical suspicion of leptomeningeal metastasis (LM).
- Trial name
- NCT02948751
- Testing
- OncoCEE
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Columbia University
Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain
Trotabresib in Combination With Vinorelbine and Radiation Therapy for the Treatment of HER2+ Breast Cancer With Central Nervous System or Leptomeningeal Metastasis
This phase I/Ib trial tests the safety, side effects, and best dose of vinorelbine when given in combination with trotabresib in treating patients with HER2 positive breast cancer that has spread to the central nervous system or…
- Conditions
- Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Neoplasm in the Leptomeninges
- Trial name
- NCT06137651
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- United States
- Sponsor
- Northwestern University
Peritoneal Carcinomatosis
PIPAC With Nab-paclitaxel and Cisplatin in Peritoneal Carcinomatosis
Phase Ib trial including investigating the combination of nab-paclitaxel and cisplatin in patients diagnosed with peritoneal carcinomatosis related to pancreatic, oeso-gastric, ovarian cancer or primitive peritoneal mesothelioma.
- Trial name
- Nab-PIPAC (NCT04000906)
- Testing
- Nab paclitaxel, Cisplatin
- Where
- 2 sites in Switzerland
- Volunteers
- 18 people
- Sponsor
- University Hospital, Geneva
Leptomeningeal Metastasis, Immune Checkpoint Inhibitor
Clinical Observation of ICI Combined With Recombinant Human Endostatin on Leptomeningeal Metastasis of Lung Cancer
immune checkpoint inhibitor combined with recombinant human endostatin can improve the 3-month OS rate of leptomeningeal metastasis of lung cancer, and the combination is safe
- Conditions
- Leptomeningeal Metastasis, Immune Checkpoint Inhibitor, Endostatin
- Trial name
- NCT05385185
- Testing
- Camrelizumab or envafolimab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Hebei Medical University
Neoplastic Meningitis
Phase 1 Intrathecal Topotecan for Neoplastic Meningitis
1. To find the optimal dose of topotecan that can safely be given directly into the spinal fluid (called intrathecal administration) of children whose cancer has spread to the lining of the brain and/or spinal cord. 2.
- Trial name
- PBTC-019 (NCT00674674)
- Testing
- Topotecan
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Baylor College of Medicine
Peritoneal Carcinomatosis, Peritoneal Metastases
Diagnostic Value of Diffusion-weighted Magnetic Resonance in High-risk Colorectal and Appendiceal Neoplasms
Diffusion-weighted magnetic resonance imaging (DWI/MRI) has been described in recent literature as a highly sensitive and specific modality for the detection of peritoneal metastases PM.
- Conditions
- Peritoneal Carcinomatosis, Peritoneal Metastases, Appendix Cancer, Appendix Neoplasm
- Trial name
- DWI-HighRisk (NCT05623787)
- Testing
- Whole-body diffusion-weighted magnetic resonance imaging
- Where
- 2 sites in Canada
- Volunteers
- 30 people
- Sponsor
- Laval University
Peritoneal Carcinomatosis
A Nomogram to Predict Major Postoperative Complications After Cytoreductive Surgery and HIPEC Based on Pre and Peroperative Criteria: Which Patient Require Intensive Monitoring?
In this study, the investigators tend to highlight pre and peroperative factors that predict major postoperative complication after a surgery for resection of peritoneal carcinomatosis.
- Trial name
- NCT05547568
- Testing
- Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy
- Where
- France
- Volunteers
- 219 people
- Sponsor
- CHU de Reims
Peritoneum Cancer, Peritoneal Carcinomatosis
Adjuvant Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in Resected High Risk Colon Cancer Patients
In this study, patients will be offered two Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) treatments with oxaliplatin after primary resection and standard adjuvant chemotherapy (if indicated) for colon cancer.
- Conditions
- Peritoneum Cancer, Peritoneal Carcinomatosis, Peritoneal Metastases, Colo-rectal Cancer
- Trial name
- NCT03280511
- Testing
- PIPAC
- Where
- Denmark
- Volunteers
- 60 people
- Sponsor
- Michael Bau Mortensen
Carcinoma
Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer
This study is to test escalating doses of intraperitoneal (IP) oxaliplatin in conjunction with systemic bevacizumab and capecitabine in patients with Peritoneal Carcinomatosis (PC) from either appendiceal or colorectal…
- Trial name
- NCT01061515
- Testing
- Intraperitoneal Oxaliplatin, Bevacizumab, Capecitabine
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Washington University School of Medicine
Leptomeningeal Metastasis, Non-small Cell Lung Cancer
Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis
Leptomeningeal metastasis (LM) is a devastating and terminal complication of advanced non-small-cell lung cancer (NSCLC), especially in patients harboring epidermal growth factor receptor (EGFR) mutations.
- Conditions
- Leptomeningeal Metastasis, Non-small Cell Lung Cancer, EGFR Activating Mutation
- Trial name
- OWONBNSCLCLM (NCT04148898)
- Testing
- Osimertinib, Bevacizumab
- Volunteers
- 80 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
Colorectal Cancer, Peritoneal Metastases
Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial")
To find the highest dose of NK cells that can be given by vein and intraperitoneally (given directly into the abdominal cavity) in combination with cetuximab to patients with colorectal cancer that has spread to the peritoneum.
- Conditions
- Colorectal Cancer, Peritoneal Metastases, Carcinomatosis
- Trial name
- NCT07411599
- Testing
- Cyclophosphamide, Fludarabine, Cetuximab
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- M.D. Anderson Cancer Center
Malignant Neoplasm, Metastatic Malignant Neoplasm in the Brain
HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases
This phase I trial studies the side effects and best dose of HER2-CAR T cells in treating patients with cancer that has spread to the brain or leptomeninges and has come back (recurrent).
- Conditions
- Malignant Neoplasm, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Neoplasm in the Leptomeninges, Breast Cancer
- Trial name
- NCT03696030
- Testing
- Chimeric Antigen Receptor T-Cell Therapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- City of Hope Medical Center
Leptomeningeal Metastasis
Concurrent Intrathecal-pemetrexed and Involved-field Radiotherapy for Leptomeningeal Metastasis From Solid Tumors
Intrathecal chemotherapy is one of the most important treatment modalities for leptomeningeal metastasis of solid tumors. In the previous retrospective study, it has been proved that concurrent radiotherapy and intrathecal…
- Trial name
- NCT03507244
- Testing
- Pemetrexed, Dexamethasone, Radiotherapy
- Where
- China
- Volunteers
- 34 people
- Sponsor
- The First Hospital of Jilin University
Peritoneal Carcinomatosis
Role of Intraperitoneal Intraoperative Chemotherapy With Paclitaxel in the Surgical Treatment of Peritoneal Carcinomatosis From Ovarian Cancer. Hyperthermia Versus Normothermia
A randomized controlled single-blind clinical trial was performed, in 32 patients diagnosed with peritoneal carcinomatosis from epithelial ovarian cancer, who underwent radical surgery-peritonectomy, achieving an optimal R0-R1…
- Trial name
- NCT02739698
- Testing
- Paclitaxel, Radical surgery-peritonectomy
- Volunteers
- 32 people
- Sponsor
- Maimónides Biomedical Research Institute of Córdoba
Leptomeningeal Metastasis, Pemetrexed
Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis
This phase I/II study is to evaluate the recommended dose, safety, feasibility, and therapeutic response of intrathecal dual checkpoint inhibitor (targeting PD-1 and CTLA-4 with QL1706) in combination with pemetrexed in patients…
- Conditions
- Leptomeningeal Metastasis, Pemetrexed, PD-1 Inhibitor, CTLA4
- Trial name
- NCT06809530
- Testing
- QL1706 (bispecific antibody targeting PD-1 and CLTA-4), Pemetrexed (Alimta)
- Where
- 5 sites in China
- Volunteers
- 39 people
- Sponsor
- Guangzhou Medical University
Solid Tumour Neoplastic Meningitis, Brain Metastases
Study to Demonstrate the Safety of WBR Administered at the Same Time as Intrathecal Liposomal Cytarabine (DepoCyte®) Versus Intrathecal Liposomal Cytarabine (DepoCyte®) Administered After WBR for the Treatment of Solid Tumour Neoplastic Meningitis in Patients With or Without Brain Metastasis.
The purpose of this study is to demonstrate the safety of giving Whole Brain Radiotherapy (WBRT) together with intrathecal liposomal cytarabine (DepoCyte®) for patients with leptomeningeal metastases.
- Trial name
- NCT00854867
- Testing
- Whole Brain Radio Therapy (WBRT) with sequential Depocyte, Whole brain radiotherapy (WBRT) with concomitant Depocyte
- Where
- 7 sites in Austria, Germany
- Volunteers
- 18 people
- Sponsor
- Mundipharma Research Limited
Gastric Cancer, Peritoneal Carcinomatosis
Randomized Controlled Trial to Prevent Peritoneal Seeding in Gastric Cancer
Randomized Controlled Trial to Prevent Peritoneal Seeding in Gastric Cancer
- Trial name
- HIPECStomach (NCT01683864)
- Testing
- positive cytology with HIPEC
- Where
- Germany
- Volunteers
- 3 people
- Sponsor
- University Hospital Tuebingen